Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157

Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157

  • Preclinical data support evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors
  • FPA157 is an anti-CCR8 antibody engineered to enhance antibody-dependent cell-mediated cytotoxicity to preferentially eliminate CCR8+ Treg cells in the tumor microenvironment
  • Data presented today at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) show investigational immunotherapy FPA157 elicits anti-tumor activity in multiple preclinical models
  • FPT157 is undergoing IND-enabling studies

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today presented the first preclinical data from its anti-CCR8 FPA157 program at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).

The poster, “Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells,” was presented in a late-breaker live Q&A session and is available here.

Key highlights from the poster included:

  • CCR8 expression is highly restricted to T regulatory (Treg) cells within the tumor
  • Preclinical efficacy studies demonstrate that anti-CCR8 antibody treatment depletes CCR8+ Tregs in the tumor microenvironment while sparing peripheral Treg subsets
  • Anti-CCR8 treatment elicits the development of robust anti-tumor memory responses
  • FPA157 leads to potent natural killer (NK) cell-dependent killing of CCR8+ target cells

“Preclinical data for FPA157 suggest that selective depletion of regulatory T cells within the tumor— without affecting peripheral Tregs—is a promising and exciting therapeutic pathway to pursue,” said Andrew Rankin, PhD, Vice President of Research. “This is the first time we are publicly sharing information about the CCR8 inhibitor antibody in the Five Prime immuno-oncology pipeline and to do so at SITC is very rewarding. We are eager to further investigate the potential of FPA157 in the clinic.”

There will be two live Q&A sessions with poster author Edwina Naik, PhD, Associate Director, Immuno-Oncology Research. The first is today, November 11, 2020 from 5:15-5:45pm EST and the second is on November 13, 2020 from 4:40-5:10pm EST.

About FPA157

FPA157 is a monoclonal antibody targeting CCR8 that is designed to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) and deplete the T regulatory cell (Treg) population in the tumor microenvironment. Tregs inhibit anti-tumoral immune responses and act through multiple suppressive mechanisms.1,2 FPA157 is part of the Five Prime immuno-oncology antibody pipeline and is undergoing IND-enabling studies.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Forward-looking statements contained in this press release include statements regarding (i) Five Prime’s expectations regarding the potential safety, efficacy or clinical utility of FPA157; and (ii) the potential use of FPA157 to treat certain patients. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during research, preclinical or clinical studies, changes in expected or existing competition, changes in the regulatory, pricing or reimbursement environment, and unexpected litigation or other disputes. In addition, while the company expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on the company’s ability to advance its manufacturing, clinical development and regulatory efforts and business and corporate development and other objectives and the value of and market for its common stock will depend on future developments that are highly uncertain, and the company cannot predict with confidence the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries and the effectiveness of actions taken globally to contain and treat COVID-19. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

References

  1. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth [published correction appears in Cancer Res. 2010; 70(23):10014]. Cancer Res. 2010; 70(20):7800-7809. doi:10.1158/0008-5472.CAN-10-1681
  2. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013; 210(9):1695-710. doi:10.1084/jem.20130579

Source: Five Prime Therapeutics, Inc.

Media and Investor Contact

Martin Forrest

VP, Investor Relations & Corporate Communications

Five Prime Therapeutics, Inc.

415-365-5625

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Stem Cells Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

VISLINK TECHNOLOGIES, INC. Third Quarter 2020 Earnings Update 

HACKETTSTOWN, NJ, Nov. 11, 2020 (GLOBE NEWSWIRE) — Vislink Technologies, Inc. (NASDAQ: VISL) (the “Company”) plans to release the results of its third quarter (ended September 30, 2020) on Thursday, November 12, 2020. On Friday November 13, 2020, Vislink’s CEO, Carleton Miller, and CFO, Michael Bond, will host a webcast at approximately 10:00 a.m. ET to give the Q3 earnings update. This webcast will be live at https://services.choruscall.com/links/visl201113.html. Investors will be able to submit questions during the webcast.

About Vislink Technologies, Inc.

Vislink Technologies is a global leader in the development and distribution of advanced communication solutions. Driven by technical excellence that has led the industry for over 50 years, our innovative products and turnkey solutions provide reliable connectivity in the toughest environments across the global live production, military and government sectors. Our solutions include high-definition communication links that reliably capture, transmit and manage live event footage, as well as secure video systems that support mission-critical applications. Vislink Technologies shares are publicly traded on the Nasdaq Capital Market under the ticker symbol VISL. For more information, visit www.vislink.com.

Note on Forward-looking Statements

This press release may contain projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements involve risks and uncertainties, and actual events or results may differ materially. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are the risk that our reduction in operating expenses may impact our ability to meet our business objectives and achieve our revenue targets and may not result in the expected improvement in our profitability, the fact that our future growth depends in part on further penetrating our addressable market and also growing internationally, and we may not be successful in doing so; our dependence on sales of certain products to generate a significant portion of our revenue; the effect of a decrease in the sales or change in sales mix of these products would harm our business; the risks that an economic downturn or economic uncertainty in our key U.S. and international markets may adversely affect demand for our products; difficulty in accurately predicting our future customer demand; the importance of maintaining the value and reputation of our brand; and other factors detailed in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof or as of the date otherwise stated herein. The Company disclaims any obligation to update these forward-looking statements.

FOR MORE INFORMATION:


[email protected]

Power Financial Reports Third Quarter 2020 Financial Results

Canada NewsWire

Readers are referred to the sections “Non-IFRS Financial Measures and Presentation” and “Forward-Looking Statements” at the end of this release.

MONTRÉAL, Nov. 11, 2020 /CNW Telbec/ – Power Financial Corporation (Power Financial or the Corporation) today reported earnings results for the three and nine months ended September 30, 2020.

Power Financial
Consolidated results for the period ended September 30

Highlights

  • The Corporation’s net asset value per share (a non-IFRS financial measure, see Non-IFRS Financial Measures and Presentation later in this news release) was $33.56 at September 30, 2020, compared with $31.09 at June 30, 2020, representing an increase of 7.9%.
  • August 17, 2020: Great-West Lifeco Inc. (Lifeco)’s subsidiary Empower Retirement completed the acquisition of Personal Capital Corporation (Personal Capital), a hybrid wealth manager that combines a leading-edge digital experience with personalized advice delivered by human advisors.

  • September 8, 2020: Empower Retirement announced that it entered into an agreement to purchase the retirement services business of Massachusetts Mutual Life Insurance Company (MassMutual), strengthening Empower Retirement’s position as the second-largest player in the U.S. retirement market.

  • September 17, 2020: Mackenzie Financial Corporation (Mackenzie) and Lifeco announced a strategic relationship with Northleaf Capital Partners Ltd. (Northleaf) to expand and enhance their private markets capabilities. The transaction was completed on October 29, 2020.

  • October 14, 2020: Wealthsimple Financial Corp. (Wealthsimple) announced the closing of a $114 million investment on a pre-money valuation of $1.4 billion.

  • IGM Financial Inc. (IGM) assets under management and advisement were a record high of $196.4 billion, up 4.3% from June 30, 2020 and 6.1% from September 30, 2019. Investment fund net sales were $610 million, compared with net sales of $103 million in the third quarter of 2019.
  • IGM reported net earnings of $191 million or $0.80 per share, compared with $202 million or $0.85 per share in the third quarter of 2019. Adjusted net earnings, excluding adjustments, were $214 million or $0.90 per share, compared with $202 million or $0.85 per share in the third quarter of 2019. This is the second highest adjusted earnings per share in IGM’s history.

Third Quarter
Net earnings attributable to common shareholders were $503 million or $0.75 per share, compared with $584 million or $0.88 per share in 2019.

Adjusted net earnings attributable to common shareholders (a non-IFRS financial measure, see Non-IFRS Financial Measures and Presentation later in this news release) were $436 million or $0.65 per share, compared with $554 million or $0.83 per share in 2019.

Contributions to Power Financial’s earnings per share:


2020

2019

(in dollars per Power Financial share)


Net Earnings


Adjusted Net
Earnings

Net Earnings

Adjusted Net
Earnings

Lifeco


0.83


0.68

0.74

0.68

IGM


0.18


0.20

0.19

0.19

Pargesa/GBL


(0.02)


(0.02)

0.05

0.06


0.99


0.86

0.98

0.93

Corporate and Other [1]


(0.24)


(0.21)

(0.10)

(0.10)


0.75


0.65

0.88

0.83

Lifeco: contribution to net earnings per share increased by 12%, contribution to adjusted net earnings per share was the same.
IGM: contribution to net earnings per share decreased by 5%, contribution to adjusted net earnings per share increased by 5%.
Pargesa/GBL (Pargesa Holding SA): results reflect the impact of COVID-19 on its portfolio as well as a charge of $0.06 per share in the quarter for losses due to an increase in the put right liability of the non-controlling interests in Webhelp.
Corporate and Other: the third quarter includes a charge of $0.10 per share for the remeasurement of the put right liability of the non-controlling interests in Wealthsimple and carried interests payable, both due to the increase in the fair value of Wealthsimple.

Adjustments in the third quarter of 2020, excluded from adjusted net earnings, were a net positive impact to earnings of $67 million or $0.10 per share, mainly related to the Corporation’s share of Lifeco’s and IGM’s adjustments. Adjustments in the third quarter of 2019 were a net positive impact to earnings of $30 million or $0.05 per share, mainly related to the Corporation’s share of Lifeco’s and Pargesa’s adjustments.

[1]

Includes Power Financial corporate operations and dividends on preferred shares as well as consolidation entries; refer to the Earnings Summary below.

Nine Months
Net earnings attributable to common shareholders were $1,508 million or $2.27 per share, compared with $1,563 million or $2.29 per share in 2019.

Adjusted net earnings attributable to common shareholders were $1,476 million or $2.22 per share, compared with $1,595 million or $2.33 per share in 2019.

Contributions to Power Financial’s earnings per share:


2020

[1]

2019

(in dollars per Power Financial share)


Net Earnings


Adjusted Net
Earnings

Net Earnings

Adjusted Net
Earnings

Lifeco [2]


2.05


1.94

1.82

1.84

IGM


0.50


0.52

0.50

0.51

Pargesa/GBL


0.10


0.11

0.17

0.19


2.65


2.57

2.49

2.54

Corporate and Other [3]


(0.38)


(0.35)

(0.20)

(0.21)


2.27


2.22

2.29

2.33

Adjustments in the nine-month period of 2020, excluded from adjusted net earnings, were a net positive impact to earnings of $32 million or $0.05 per share, mainly related to the Corporation’s share of Lifeco’s and IGM’s adjustments. Adjustments in the nine-month period of 2019 were a net negative impact to earnings of $32 million or $0.04 per share, mainly related to the Corporation’s share of Lifeco’s and Pargesa’s adjustments.

[1]

The Corporation completed a substantial issuer bid in the second quarter of 2019 and repurchased 7.0% of its common shares.

[2]

The Corporation participated in Lifeco’s substantial issuer bid in the second quarter of 2019; the number of shares held by the Corporation decreased by 7.4%.

[3]

Includes Power Financial corporate operations and dividends on preferred shares as well as consolidation entries; refer to the Earnings Summary below.

Great-West Lifeco, IGM Financial and Pargesa
Results for the third quarter ended September 30

The information below is derived from Lifeco and IGM’s interim MD&As, as prepared and disclosed by the respective companies in accordance with applicable securities legislation, and which are also available either directly from SEDAR (www.sedar.com) or from their websites, www.greatwestlifeco.com and www.igmfinancial.com. The information below related to Pargesa is derived from publicly disclosed information, as issued by Pargesa in its third quarter press release. Further information on Pargesa’s results is available on its website at www.pargesa.ch.

GREAT-WEST LIFECO INC.

Net earnings attributable to common shareholders were $826 million or $0.891 per share, compared with $730 million or $0.786 per share in 2019.

Adjusted net earnings [1] attributable to common shareholders were $679 million or $0.732 per share, compared with $677 million or $0.729 per share in 2019.

Adjustments in the third quarter of 2020, excluded from adjusted net earnings, were a net positive impact to earnings of $147 million, compared with a net positive impact to earnings of $53 million in 2019. Lifeco’s adjustments in 2020 consisted of a net positive impact of actuarial assumption changes and other management actions, market-related impacts on liabilities and a net gain on the sale of Irish Progressive Services International Limited, offset by transaction costs related to the acquisitions of Personal Capital and MassMutual.

[1]

Described as “base earnings” by Lifeco. For additional information, please refer to the Non-IFRS Financial Measures and Presentation section later in this news release.

IGM FINANCIAL INC.

Net earnings available to common shareholders were $191 million or $0.80 per share, compared with $202 million or $0.85 per share in 2019. 

Adjusted net earnings available to common shareholders were $214 million or $0.90 per share, compared with $202 million or $0.85 per share in 2019.

Adjustments in the third quarter of 2020, excluded from adjusted net earnings, were a net negative impact to earnings of $23 million consisting of restructuring and other charges, offset by a gain on the sale of IGM’s investment in Personal Capital.

Assets under management and advisement at September 30, 2020 were $196.4 billion, an increase of 4.3% from June 30, 2020.

PARGESA HOLDING SA

Pargesa reported a net loss of SF23 million, compared with net earnings of SF91 million in 2019.

Adjusted net earnings were a net loss of SF21 million, compared with adjusted net earnings of SF107 million in 2019. Adjustments, not included in adjusted net earnings, were a charge of SF2 million in the third quarter, compared with a charge of SF16 million in 2019, mainly consisting of other charges at Pargesa related to Parques Reunidos Servicios Centrales, S.A. (Parques), an equity investment.

Pargesa reported a net asset value at September 30, 2020 of SF8,375 million, representing SF98.8 per share, compared with SF8,393 million or SF99.0 per share at June 30, 2020. 

Pargesa adopted IFRS 9 in 2018. The Corporation continues to apply IAS 39; this results in a negative adjustment to the contribution from Pargesa of $28 million in the third quarter of 2020. 

Parjointco N.V. (Parjointco) and Pargesa announced on March 11, 2020 a public exchange offer for all Pargesa shares not held by Parjointco to be exchanged for Groupe Bruxelles Lambert (GBL) shares. Following the successful public exchange offer, Power Financial holds an interest of 48.7% in Pargesa. Pargesa in turn holds a 29.5% in GBL. The transaction is expected to be completed in the fourth quarter of 2020.

COVID-19

The outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses globally resulting in an economic slowdown. Governments and central banks have responded with significant monetary and fiscal interventions designed to stabilize economic conditions. Equity markets in particular have been volatile, experiencing material and rapid declines in the first quarter of 2020. However, following March 31, 2020, the markets have experienced recoveries.

The Corporation is managing the risks associated with the COVID-19 pandemic utilizing its existing risk management framework. At Power Financial and its group companies, the focus has continued to be on managing the safety and well-being of its people, maintaining operational effectiveness, ensuring that the group can serve its customers, assessing impacts on earnings, liquidity and capital, planning for different potential scenarios and engaging with stakeholders. The respective boards of directors of Lifeco, IGM, Pargesa and GBL are responsible for the governance structures and processes to oversee the management of the risk and potential impacts presented by the current economic slowdown and other potential consequences due to COVID-19.

The duration and impact of the COVID-19 pandemic is unknown at this time. Economic damage and market weakness are being felt across the global economy. Significant economic headwinds are expected to continue into the fourth quarter of 2020 and beyond as a result of anticipated negative credit experiences, impairment of valuations in certain sectors of the economy and asset classes, and uncertainties in the durability and effectiveness of government and central bank interventions, among others. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Corporation and its operating subsidiaries in future periods.

Dividends on Power Financial Preferred Shares

The Board of Directors declared quarterly dividends on the Corporation’s preferred shares.

Dividends payable February 15, 2021 to shareholders of record January 25, 2021:


Series – Stock Symbol


Amount

Series A – PWF.PR.A

Floating rate [1]

[1]

Equal to one quarter of 70% of the average prime rate of two major Canadian chartered banks for the period October 1 to December 31, 2020.

Dividends payable January 31, 2021 to shareholders of record January 8, 2021:


Series


Stock Symbol


Amount


Series


Stock Symbol


Amount

Series D

PWF.PR.E

34.375¢

Series O

PWF.PR.O

36.25¢

Series E

PWF.PR.F

32.8125¢

Series P

PWF.PR.P

14.4125¢

Series F

PWF.PR.G

36.875¢

Series Q

PWF.PR.Q

10.9392¢

Series H

PWF.PR.H

35.9375¢

Series R

PWF.PR.R

34.375¢

Series I

PWF.PR.I

37.50¢

Series S

PWF.PR.S

30¢

Series K

PWF.PR.K

30.9375¢

Series T

PWF.PR.T

26.3438¢

Series L

PWF.PR.L

31.875¢

Series V

PWF.PR.Z

32.1875¢

About Power Financial

Power Financial, a wholly owned subsidiary of Power Corporation of Canada, is an international management and holding company with interests in financial services and asset management businesses in Canada, the United States and Europe. It also has significant holdings in a portfolio of global companies based in Europe. To learn more, visit www.PowerFinancial.com.

At September 30, 2020, Power Financial held the following economic interests:

[1]

Undiluted equity interest held by Lifeco, IGM and the Corporation (the Group), representing a fully diluted equity interest of 70.1%. On October 14, 2020, Wealthsimple announced the closing of a $114 million investment on a pre-money valuation of $1.4 billion. The investment was led by TCV, one of the largest growth equity investors focused on technology, along with Greylock Partners, Meritech Capital, Allianz X and Two Sigma Ventures. With the closing of the investment, the Group now has an ownership interest in Wealthsimple of 61.7% on a fully diluted basis.

Earnings Summary

Earnings

(unaudited)

Three months ended

Nine months ended

(in millions of Canadian dollars)

September 30,

September 30,


2020

2019


2020

2019


Adjusted net earnings [1] 

Lifeco [2]


454

452


1,289

1,258

IGM [2]


133

126


347

348

Pargesa [2]


(15)

40


73

130

Consolidation entries [3]


(53)

(7)


(28)

39


519

611


1,681

1,775

Corporate operations [4]


(49)

(22)


(102)

(76)

Dividends on perpetual preferred shares


(34)

(35)


(103)

(104)


Adjusted net earnings [5] 


436

554


1,476

1,595

Adjustments – see below


67

30


32

(32)


Net earnings [5] 


503

584


1,508

1,563

Earnings per Share

(unaudited)

Three months ended

Nine months ended

(in dollars per share)

September 30,

September 30,


2020

2019


2020

2019


Adjusted net earnings per share

 basic [1]

Lifeco [2]


0.68

0.68


1.94

1.84

IGM [2]


0.20

0.19


0.52

0.51

Pargesa [2]


(0.02)

0.06


0.11

0.19

Consolidation entries [3]


(0.08)

(0.01)


(0.03)

0.05


0.78

0.92


2.54

2.59

Corporate operations [4] 


(0.08)

(0.04)


(0.16)

(0.11)

Dividends on perpetual preferred shares


(0.05)

(0.05)


(0.16)

(0.15)


Adjusted net earnings per share [5] 


0.65

0.83


2.22

2.33

Adjustments – see below


0.10

0.05


0.05

(0.04)


Net earnings per share [5] 


0.75

0.88


2.27

2.29

[1]

Effective the first quarter of 2020, the Corporation introduced a modified definition of its Non-IFRS earnings measures, Adjusted net earnings. The comparative figures have been restated. For additional information, please refer to the Non-IFRS Financial Measures and Presentation section later in this news release.

[2]

As reported by Lifeco, IGM and Pargesa.

[3]

The consolidation entries include an allocation of the results of Portag3 Ventures Limited Partnership (Portag3 I), Portag3 Ventures II Limited Partnership (Portag3 II), Wealthsimple and KOHO Financial Inc. (Koho), to the contributions from Lifeco and IGM based on their respective interest. The third quarter of 2020 includes a charge of $36 million or $0.05 per share related to the allocation of the remeasurement of the put right liability of the non-controlling interests in Wealthsimple to fair value and carried interests payable. This charge was offset by IGM’s gain on Personal Capital which the Corporation has not included as an Adjustment. The consolidation entries also reflect adjustments in accordance with IAS 39 for IGM and Pargesa.

[4]

The third quarter of 2020 includes Power Financial’s share in the amount of $33 million or $0.05 per share related to the impact of the remeasurement of the put right liability of the non-controlling interests in Wealthsimple to fair value and an increase in carried interests payable.

[5]

Attributable to common shareholders.

Adjustments (not included in adjusted net earnings)

(unaudited)

Three months ended

Nine months ended

(in millions of Canadian dollars)

September 30,

September 30,


2020

2019


2020

2019

Share of Lifeco’s adjustments:

Actuarial assumption changes

and other management actions


44

54


91

167

Market-related impacts on liabilities


13

(19)


(64)

(51)

Net gain on sale of Irish Progressive Services International Limited


63


63

Transaction costs related to the acquisitions

of Personal Capital and MassMutual


(21)


(21)

Net charge on the sale, via reinsurance, of U.S. individual life

insurance and annuity business





(134)


99

35


69

(18)

Share of IGM’s adjustments [1]:

Restructuring and other charges


(34)


(34)

Share of Lifeco’s adjustments


4

1


3

(1)


(30)

1


(31)

(1)

Share of Pargesa’s adjustments:

Imerys – Impairments, restructuring charges and other


(1)


(3)

(7)

Parques and other charges


(1)

(6)


(3)

(6)


(2)

(6)


(6)

(13)


67

30


32

(32)

[1]

Includes IGM’s share of Lifeco’s Adjustments for the impact of actuarial assumption changes and management actions and market impact on insurance contract liabilities, in accordance with the Corporation’s definition of Adjusted net earnings. Excludes the Corporation’s share of IGM’s Adjustment related to the gain on disposal of Personal Capital; the Corporation has not included this amount as an Adjustment as the gain recognized by the Corporation relates to the remeasurement of the investment in Personal Capital at fair value on the date Lifeco acquired control. For additional information, please refer to the Non-IFRS Financial Measures and Presentation section later in this news release.

Contribution to Power Financial’s Adjusted Net Earnings


In millions


Per share

Three months ended September 30, 2020

(unaudited)

(in Canadian dollars)

Contribution

to adjusted
net earnings

as reported

Consolidation
entries [1]

Contribution to
Power
Financial’s

adjusted
net earnings

Contribution

to adjusted
net earnings

as reported

Consolidation
entries [1]

Contribution to
Power
Financial’s

adjusted
net earnings

Lifeco

454

(7)

447

0.68

(0.01)

0.67

IGM [2]

133

(18)

115

0.20

(0.03)

0.17

Pargesa

(15)

(28)

(43)

(0.02)

(0.04)

(0.06)

Nine months ended September 30, 2020

(unaudited)

(in Canadian dollars)

Contribution

to adjusted
net earnings

as reported

Consolidation
entries [1]

Contribution to
Power

Financial’s

adjusted
net earnings

Contribution

to adjusted
net earnings

as reported

Consolidation
entries [1]

Contribution to
Power
Financial’s

adjusted
net earnings

Lifeco

1,289

(10)

1,279

1.94

(0.01)

1.93

IGM [2]

347

(23)

324

0.52

(0.03)

0.49

Pargesa

73

5

78

0.11

0.01

0.12

[1]

The contributions from Lifeco and IGM include an allocation of the results of Portag3 I, Portag3 II, Wealthsimple and Koho, based on their respective interest. The contributions from IGM and Pargesa reflect adjustments in accordance with IAS 39.

[2]

In the third quarter of 2020, the adjustment of IGM mainly relates to the allocation of the remeasurement of the put right liability of the non-controlling interests in Wealthsimple to fair value and carried interests payable. This charge was offset by IGM’s gain on Personal Capital which the Corporation has not included as an Adjustment; the Corporation has not included this amount as an Adjustment as the gain recognized by the Corporation relates to the remeasurement of the investment in Personal Capital at fair value on the date Lifeco acquired control.

Adjustments to Pargesa’s Contribution

Power Financial has deferred the adoption of IFRS 9 and continues to apply IAS 39. The following table presents adjustments to the contribution of Pargesa to Power Financial’s earnings in accordance with IAS 39:

(unaudited)

2020

(in millions of Canadian dollars)

Q3

Q2

Q1

Total

Disposal of interest in Total SA [1]

70

70

Impairment charges [1]  

(7)

(5)

(40)

(52)

Disposal of private equity funds and other

(2)

(4)

20

14

Reversal of unrealized (gains) losses on private equity funds and

other [2]

(19)

(33)

25

(27)

Total

(28)

(42)

75

5

[1] 

On January 1, 2018, Pargesa adopted IFRS 9 which resulted in the reclassification of the majority of its investments (excluding private equity funds) from available for sale (AFS) to fair value through other comprehensive income (FVOCI). All changes in fair value of equity investments designated as FVOCI are recognized permanently in other comprehensive income. Power Financial continues to apply IAS 39 and has adjusted its share of these items.

[2]

Pargesa classifies private equity investments at fair value through profit and loss in accordance with IFRS 9 and recognizes unrealized changes in fair value in earnings. Power Financial does not recognize these unrealized fair value changes in earnings as it continues to classify these private equity funds as available for sale in accordance with IAS 39.        

Net Asset Value

Net asset value represents management’s estimate of the fair value of the common shareholders’ equity of the Corporation. Net asset value is the fair value of Power Financial’s non-consolidated assets less its net debt and preferred shares.

The Corporation’s net asset value per share was $33.56 at September 30, 2020, compared with $31.09 at June 30, 2020, representing an increase of 7.9%.

September 30, 2020

(in millions of Canadian dollars,

except per share amounts)

Non-consolidated
balance sheet

Fair value
adjustment

Net asset value


Assets

Investments

Lifeco 

14,291

1,848

16,139

IGM

2,776

1,740

4,516

Pargesa/GBL [1]

3,860

(1,182)

2,678

Other [2] 

152

362

514

Cash and cash equivalents

1,002

1,002

Other assets [3] 

801

801

Total assets

22,882

2,768

25,650


Liabilities and preferred shares

Debentures

250

250

Other liabilities [4]  

284

284

Perpetual preferred shares

2,830

2,830

Total liabilities and preferred shares

3,364

3,364


Net value

Common shareholders’ equity / Net asset value

19,518

2,768

22,286


Per share


29.39


33.56

[1]

As part of the Pargesa reorganization, Parjointco holds approximately 97% of Pargesa’s shares at September 30, 2020; the fair value of Parjointco at September 30, 2020 is based on the market value of GBL.

[2]

Fair value adjustment is related to Power Financial’s investments in Portag3 I, Portag3 II, Wealthsimple and Koho.

[3]

Includes promissory notes from Power Corporation of $664 million at September 30, 2020 (refer to the section “Transactions with Related Parties” in the interim MD&A) and $83 million of dividends declared in the third quarter by IGM and received by the Corporation on October 30, 2020.

[4]

In accordance with IAS 12, Income taxes, no deferred tax liability is recognized with respect to temporary differences associated with investments in subsidiaries and jointly controlled corporations as the Corporation is able to control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future. If the Corporation were to dispose of an investment in a subsidiary or a jointly controlled corporation, income taxes payable on such disposition would be minimized through careful and prudent tax planning and structuring, as well as with the use of available tax attributes not otherwise recognized on the balance sheet, including tax losses, tax basis, safe income and foreign tax surplus associated with the subsidiary or jointly controlled corporation.

Non-IFRS Financial Measures and Presentation

Effective the first quarter of 2020, the Corporation introduced a modified definition of its non-IFRS earnings measure, Adjusted net earnings. This change is consistent with the introduction of base earnings (loss) by Lifeco which was introduced in the first quarter of 2020 to reflect management’s view of the operating performance of Lifeco. Lifeco defines base earnings (loss) as net earnings excluding the impact of actuarial assumption changes and management actions, direct equity and interest rate market impacts on insurance contract liabilities net of hedging, and items that management believes are not indicative of the company’s underlying business results. The definition of Adjustments includes what the Corporation previously presented as other items and also includes Lifeco’s impact of actuarial assumption changes and management actions, and direct equity and interest rate market impacts on insurance contract liabilities net of hedging. The definition of Adjustments used in Adjusted net earnings is being adopted to enhance comparability of results between reporting periods and in anticipation of Lifeco’s implementation of accounting changes related to IFRS 17, Insurance Contracts, on January 1, 2023. The comparative periods have been restated to reflect the introduction of this modified measure.

Net earnings attributable to common shareholders are comprised of:

  • Adjusted net earnings attributable to common shareholders; and
  • Adjustments, which include the after-tax impact of any item that in management’s judgment would make the period-over-period comparison of results from operations less meaningful. Adjustments include the Corporation’s share of Lifeco’s impact of actuarial assumption changes and management actions, direct equity and interest rate market impacts on insurance contract liabilities net of hedging, as well as items that management believes are not indicative of the underlying business results which include those identified by a subsidiary or a jointly controlled corporation.

Management uses these financial measures in its presentation and analysis of the financial performance of Power Financial and believes that they provide additional meaningful information to readers in their analysis of the results of the Corporation. Adjusted net earnings, as defined by the Corporation, assist the reader in comparing the current period’s results to those of previous periods as it reflects management’s view of the operating performance of the Corporation and its subsidiaries and excludes items that are not considered to be part of the underlying business results from this non-IFRS financial measure.

Adjusted net earnings attributable to common shareholders and adjusted net earnings per share are non-IFRS financial measures that do not have a standard meaning and may not be comparable to similar measures used by other entities.

The Corporation also uses a non-consolidated basis of presentation to present and analyze its results whereby the Corporation’s interests in Lifeco, IGM, Portag3 I, Portag3 II, Wealthsimple and Koho are accounted for using the equity method. Presentation on a non-consolidated basis is a non-IFRS presentation. However, it is useful to the reader as it presents the holding company’s (parent) results separately from the results of its operating subsidiaries.

Net asset value is commonly used by holding companies to determine their value. Net asset value is the fair value of Power Financial’s non-consolidated assets less its net debt and preferred shares. The investments held in public entities (Lifeco, IGM and GBL (through Parjointco)) are measured at their market value and investments in private entities are measured at management’s estimate of fair value. Pargesa’s net asset value is determined on the basis of current market values for listed shareholdings, plus the fair value of private equity activities and GBL treasury shares, less net debt. This measure presents the fair value of the net assets of the holding company to management and investors and assists the reader in determining the value of the holding company.

This news release may also contain other non-IFRS financial measures which are publicly disclosed by the Corporation’s subsidiaries such as sales, assets under management and assets under administration. Refer to the “Non-IFRS Financial Measures and Presentation” section of the Corporation’s most recent Management’s Discussion and Analysis for the definition of non-IFRS financial measures and their reconciliation with IFRS financial measures.

Eligible Dividends

For purposes of the Income Tax Act (Canada) and any similar provincial legislation, all of the above dividends on the Corporation’s preferred shares are eligible dividends.

Forward-Looking Statements

Certain statements in this news release, other than statements of historical fact, are forward-looking statements based on certain assumptions and reflect the Corporation’s current expectations, or with respect to disclosure regarding the Corporation’s public subsidiaries, reflect such subsidiaries’ disclosed current expectations. Forward-looking statements are provided for the purposes of assisting the reader in understanding the Corporation’s financial performance, financial position and cash flows as at and for the periods ended on certain dates and to present information about management’s current expectations and plans relating to the future and the reader is cautioned that such statements may not be appropriate for other purposes. These statements may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies and outlook of the Corporation and its subsidiaries, including the fintech strategy, the expected impact of the COVID-19 pandemic on the Corporation and its subsidiaries’ operations, results and dividends, as well as the outlook for North American and international economies for the current fiscal year and subsequent periods, and the proposed redemption by the Corporation and Power Corporation of certain classes of their First Preferred Shares. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as “expects”, “anticipates”, “plans”, “believes”, “estimates”, “seeks”, “intends”, “targets”, “projects”, “forecasts” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may”, “will”, “should”, “would” and “could”.

By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, many of which are beyond the Corporation’s and its subsidiaries’ control, affect the operations, performance and results of the Corporation and its subsidiaries and their businesses, and could cause actual results to differ materially from current expectations of estimated or anticipated events or results. These factors include, but are not limited to: the impact or unanticipated impact of general economic, political and market factors in North America and internationally, fluctuations in interest rates, inflation and foreign exchange rates, monetary policies, business investment and the health of local and global equity and capital markets, management of market liquidity and funding risks, risks related to investments in private companies and illiquid securities, risks associated with financial instruments, changes in accounting policies and methods used to report financial condition (including uncertainties associated with significant judgments, estimates and assumptions), the effect of applying future accounting changes, business competition, operational and reputational risks, technological changes, cybersecurity risks, changes in government regulation and legislation, changes in tax laws, unexpected judicial or regulatory proceedings, catastrophic events, man-made disasters, terrorist attacks, wars and other conflicts, or an outbreak of a public health pandemic or other public health crises (such as COVID-19), the Corporation’s and its subsidiaries’ ability to complete strategic transactions, integrate acquisitions and implement other growth strategies, and the Corporation’s and its subsidiaries’ success in anticipating and managing the foregoing factors.

The reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances, including the availability of cash to redeem First Preferred Shares and that the list of factors in the previous paragraph, collectively, are not expected to have a material impact on the Corporation and its subsidiaries. While the Corporation considers these assumptions to be reasonable based on information currently available to management, they may prove to be incorrect.

Other than as specifically required by applicable Canadian law, the Corporation undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Additional information about the risks and uncertainties of the Corporation’s business and material factors or assumptions on which information contained in forward-looking statements is based is provided in its disclosure materials, including its most recent Management’s Discussion and Analysis and Annual Information Form, filed with the securities regulatory authorities in Canada and available at www.sedar.com.

SOURCE Power Financial Corporation

Consumer Portfolio Services’ Board of Directors Unanimously Rejects Unsolicited Indication of Interest from Auto Experience Inc.

LAS VEGAS, Nov. 11, 2020 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that its board of directors unanimously rejected Auto Experience Inc.’s (“AEI”) unsolicited indication of interest in acquiring the Company. 

After careful review and consideration, the CPS board concluded that AEI’s indicated price of $135 million grossly undervalues the Company. Taking into account the Company’s long-term prospects, the board determined that pursuing such a transaction would not be in the best interests of the Company’s shareholders. In addition, the CPS board does not believe that AEI’s indication of interest is credible.


About Consumer Portfolio Services, Inc.

Consumer Portfolio Services, Inc. is an independent specialty finance company that provides indirect automobile financing to individuals with past credit problems, low incomes or limited credit histories. CPS purchases retail installment sales contracts primarily from franchised automobile dealerships secured by late model used vehicles and, to a lesser extent, new vehicles. CPS funds these contract purchases on a long-term basis through the securitization markets and services the loans over their entire contract terms.


Investor Relations Contact

Jeffrey P. Fritz, Chief Financial Officer
844-878-CPSS (844-878-2777)

PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 11:20 a.m. EST.

The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:

John Sharp

PhaseBio Pharmaceuticals, Inc.

Chief Financial Officer

(610) 981-6506

[email protected]

Media Contact:

Will Zasadny

Canale Communications, Inc.

[email protected]

619-961-8848

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Science Cardiology Other Science Biotechnology Research Pharmaceutical General Health Health

MEDIA:

Logo
Logo

Leagh Turner Appointed to Manulife’s Board of Directors

PR Newswire

C$ unless otherwise stated 
TSX/NYSE/PSE: MFC     SEHK: 945

TORONTO, Nov. 11, 2020 /PRNewswire/ – Manulife today announced that Leagh Turner has been appointed to its Board of Directors, effective November 10, 2020.

A seasoned global executive in the technology sector, Ms. Turner currently holds the position of President and Chief Operating Officer for Ceridian HCM Holding Inc., a global human capital management software company. She is also a strong advocate for the advancement of women in leadership and has been recognized twice on the WXN (Women’s Executive Network) Canada’s Top 100 Most Powerful Women list.

“Leagh brings extensive leadership expertise leveraging people, process and technology to drive organizational transformation. This expertise will be exceptionally valuable in supporting Manulife’s strategy and especially our focus on being a digital customer leader,” said John Cassaday, Chairman of the Board, Manulife. “We are delighted to welcome her to our Board.”

Ms. Turner joins the Manulife Board’s Management Resources and Compensation Committee and Risk Committee.

Visit Manulife.com for more information on the Company’s Board of Directors and Corporate Governance.

About Manulife

Manulife Financial Corporation is a leading international financial services group that helps people make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across our offices in Canada, Asia, and Europe, and primarily as John Hancock in the United States. We provide financial advice, insurance, and wealth and asset management solutions for individuals, groups and institutions. At the end of 2019, we had more than 35,000 employees, over 98,000 agents, and thousands of distribution partners, serving almost 30 million customers. As of September 30, 2020, we had $1.3 trillion (US$943 billion) in assets under management and administration, and in the previous 12 months we made $31.2 billion in payments to our customers. Our principal operations are in Asia, Canada and the United States where we have served customers for more than 155 years. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges and under ‘945’ in Hong Kong.

Cision View original content:http://www.prnewswire.com/news-releases/leagh-turner-appointed-to-manulifes-board-of-directors-301171387.html

SOURCE Manulife Financial Corporation

Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20





Event


will provide an overview


of how


A


s


cendis


is applying


its


TransCon
technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology

COPENHAGEN, Denmark, Nov. 11, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will host a virtual Oncology R&D Day on Friday, November 20, 2020.

The event will provide an overview on the company’s strategy to apply the TransCon technology platform, which has been clinically validated in endocrinology rare disease, to our second therapeutic area of oncology to create product opportunities that have the potential to represent a paradigm shift in treating patients with cancer.

The event will include updates on Ascendis’ two leading oncology programs: TransCon TLR7/8 Agonist and TransCon IL-2 β/γ, for long-lasting activation of Toll-like receptor (TLR)7/8 or interleukin-2 ( IL-2) receptor β/γ, respectively.

Oncology
R&D
Day
Conference Call and Webcast information

Ascendis Pharma will host a conference call and webcast on Friday, November 20, 2020 at 12:00 p.m. Eastern Time (ET) to provide an overview and update the company’s oncology product pipeline. Details include:

Date November 20, 2020
Time 12:00 p.m. to 1:30 p.m. ET
Dial In (U.S.) 844-290-3904
Dial In (International) 574-990-1036
Access Code 8695366

A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S 

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ strategy to create product opportunities that have the potential to represent a completely new paradigm shift in treating patients with cancer, (ii) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharmaceutical company, (iii) Ascendis’ product pipeline and expansion into additional therapeutic areas and (iv) Ascendis’ expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities and the effects on its business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on July 9, 2020 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © November 2020 Ascendis Pharma A/S.


Investor contacts:

Media contact:
Tim Lee Ron Rogers
Ascendis Pharma Ascendis Pharma
(650) 374-6343 (650) 507-5208
[email protected] [email protected]
   
Patti Bank  
Westwicke Partners  
(415) 513-1284  
[email protected]  
[email protected]  

ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action – BMRN

ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action – BMRN

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.

To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-1960.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (3) as a result, BioMarin’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1960.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

TerraForm Power Operating 2020 Third Quarter Results Webcast and Conference Call

Date:
Monday
,
November
1
6
,
20
20

Time:
9
:
0
0 a.m. (Eastern Time)

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — You are invited to participate in TerraForm Power Operating, LLC’s 2020 Third Quarter Results Webcast and Conference Call on Monday, November 16, 2020 at 9:00 a.m. (Eastern Time) to discuss results and current business initiatives with senior management.

These results will be made available on our website at www.terraformpower.com in the form of a quarterly report under “Financials & SEC Filings” in advance of the conference call.

The conference call can be accessed via webcast on November 16, 2020 at 9:00 a.m. (Eastern Time) at https://edge.media-server.com/mmc/p/2s4ygu8m. A replay of the webcast will be available for those unable to attend the live webcast. To participate via teleconference, please dial 1-844-464-3938 toll free in North America, or 1-765-507-2638 for overseas calls at approximately 8:50 a.m. Eastern Time; conference ID: 2059989.

About TerraForm Power
Operating, LLC

TerraForm Power Operating, LLC owns and operates a renewable power portfolio of solar and wind assets located primarily in North America and Western Europe. The company is a controlled affiliate of Brookfield Renewable Partners L.P. For more information, please visit: www.terraformpower.com.

Contact for Investors / Media:

Sherif El-Azzazi
TerraForm Power Operating, LLC
[email protected]

T-Mobile US, Inc. to Present at the BCG and New Street Research 5G Conference

T-Mobile US, Inc. to Present at the BCG and New Street Research 5G Conference

BELLEVUE, Wash.–(BUSINESS WIRE)–
Neville Ray, president of technology of T-Mobile US, Inc. (NASDAQ: TMUS), will present and provide a business update on Tuesday, November 17, 2020 at 11:20 a.m. Eastern Time (ET) at the BCG and New Street Research 5G Conference.

A live webcast of the virtual event will be available on the Company’s Investor Relations website at http://investor.t-mobile.com. An on-demand replay will be available shortly after the conclusion of the presentation.

To automatically receive T-Mobile financial news by e-mail, please visit the T-Mobile Investor Relations website, http://investor.t-mobile.com, and subscribe to E-mail Alerts.

About T-Mobile US, Inc.

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: http://www.t-mobile.com.

Investor Contact:

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo